Literature DB >> 16643442

The pathogenesis of immune thrombocytopaenic purpura.

Nichola Cooper1, James Bussel.   

Abstract

Immune thrombocytopaenic purpura (ITP) is an autoimmune bleeding disease that is rarely fatal. However, in many adults treatment is unsatisfactory, with as much morbidity from the immunosuppressive effects of treatment as from bleeding. Identifying the underlying disease process should help us to identify more targeted therapies and improve not only the treatment but also the quality of life of patients with this disorder.

Entities:  

Mesh：

Year:  2006        PMID： 16643442     DOI： 10.1111/j.1365-2141.2006.06024.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  55 in total

1.  Bmi-1 regulates autoreactive CD4+ T cell survival in immune thrombocytopenia patients.

Authors:  Li Ma; Zeping Zhou; Donglei Zhang; Hongmei Wang; Huiyuan Li; Feng Xue; Renchi Yang
Journal:  J Clin Immunol       Date:  2012-06       Impact factor: 8.317

Review 2.  Genetic studies in pediatric ITP: outlook, feasibility, and requirements.

Authors:  Anke K Bergmann; Rachael F Grace; Ellis J Neufeld
Journal:  Ann Hematol       Date:  2010-03-23       Impact factor: 3.673

3.  The management of immune thrombocytopenic purpura.

Authors:  B I Chosamata
Journal:  Malawi Med J       Date:  2015-09       Impact factor: 0.875

4.  Romiplostim as early treatment for refractory primary immune thrombocytopenia.

Authors:  Anne Contis; Estibaliz Lazaro; Carine Greib; Jean-Luc Pellegrin; Jean-François Viallard
Journal:  Int J Hematol       Date:  2013-09-26       Impact factor: 2.490

5.  Initial Lymphocyte Count as Prognostic Indicator for Childhood Immune Thrombocytopenia.

Authors:  Sinan Akbayram; Kamuran Karaman; Murat Dogan; Lokman Ustyol; Mesut Garipardic; Ahmet Faik Oner
Journal:  Indian J Hematol Blood Transfus       Date:  2016-03-08       Impact factor: 0.900

6.  Idiopathic thrombocytopenia and Helicobacter pylori infection: platelet count increase and early eradication therapy.

Authors:  Dino Veneri; Anna Bonani; Massimo Franchini; Andrea Fedrizzi; Giovanni Pizzolo
Journal:  Blood Transfus       Date:  2011-01-13       Impact factor: 3.443

Review 7.  Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders.

Authors:  M C Levesque
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

8.  B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells.

Authors:  Matthieu Mahévas; Pauline Patin; François Huetz; Marc Descatoire; Nicolas Cagnard; Christine Bole-Feysot; Simon Le Gallou; Mehdi Khellaf; Olivier Fain; David Boutboul; Lionel Galicier; Mikael Ebbo; Olivier Lambotte; Mohamed Hamidou; Philippe Bierling; Bertrand Godeau; Marc Michel; Jean-Claude Weill; Claude-Agnès Reynaud
Journal:  J Clin Invest       Date:  2012-12-17       Impact factor: 14.808

9.  A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia.

Authors:  Mehdi Khellaf; Jean-François Viallard; Mohamed Hamidou; Stéphane Cheze; Françoise Roudot-Thoraval; François Lefrere; Olivier Fain; Sylvain Audia; Jean-François Abgrall; Jean-Marie Michot; Charles Dauriac; Sophie Lefort; Emmanuel Gyan; Mathilde Niault; Jean-Marc Durand; Laetitia Languille; David Boutboul; Philippe Bierling; Marc Michel; Bertrand Godeau
Journal:  Haematologica       Date:  2013-02-26       Impact factor: 9.941

10.  Identification of predictive factors for response to intravenous immunoglobulin treatment in children with immune thrombocytopenia.

Authors:  Yoshihito Morimoto; Nao Yoshida; Nozomu Kawashima; Kimikazu Matsumoto; Koji Kato
Journal:  Int J Hematol       Date:  2014-02-27       Impact factor: 2.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.